125 results
Page 4 of 7
8-K
EX-99.1
58g8prq82wl0
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.1
7wgtvn1f wv54tg61nq
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
8-K/A
ft5 31l709ci
6 Mar 19
Entry into a Material Definitive Agreement
5:02pm
8-K/A
EX-10.1
oz5796l5 teh14l
6 Mar 19
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
mv45kjs9fyxs6thysyu
4 Mar 19
Entry into a Material Definitive Agreement
7:05am
424B5
sbmnu0v
19 Feb 19
Prospectus supplement for primary offering
8:39am
8-K
EX-99.2
h6lnbuz7efioxll
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
tx28py1icq
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
4eh77kn6r 356dpxw
7 Jan 19
Other Events
7:01am
8-K
EX-10.1
6pr 4iaau8fggsbu
4 Jan 19
Entry into a Material Definitive Agreement
4:23pm
8-K
EX-99.1
3000f2pyx
10 Dec 18
Other Events
2:07pm
8-K
EX-99.1
txt ap5w0
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.2
8lqpbb0j1k6h s45l0
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
8msigdq8zh7
9 Oct 18
Recro Pharma Announces PDUFA Date for IV Meloxicam
6:07am
8-K
EX-99.2
uj12erjg575ke1 mioso
1 Oct 18
Recro Announces Expansion of CDMO Service Capabilities
12:00am